NDAPERIODONTALGEL
Approved
Dec 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORAQIX is a topical anesthetic gel combining lidocaine and prilocaine for periodontal procedures. It provides local anesthesia via a periodontal delivery route, numbing tissue prior to scaling and root planing or other dental interventions. The combination of two amide local anesthetics offers rapid onset and adequate duration for office-based periodontal treatment.
LOE Approaching
With LOE approaching, this product is transitioning into maintenance or decline phase, likely reducing core team headcount and shifting focus to cost management and generic transition strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORAQIX currently has zero linked job openings, reflecting its mature and declining lifecycle. Roles on this product typically center on commercial excellence and generic transition management rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on ORAQIX at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.